ARIAD Pharmaceuticals

JP Morgan has raised the price target on Ariad Pharmaceuticals (NASDAQ: ARIA) from $10 to $13 and maintains its Overweight rating.

Jefferies provided color on Ariad Pharmaceuticals (NASDAQ: ARIA). In a research report published today, Jefferies commented on the company's drug ridaforolimus. In the report, Jefferies states, "Given that there are no established options for 2nd-line endometrial cancer, we view ridaforolimus...

Brean Murray Carret & Company has raised the price target on Ariad Pharmaceuticals (NASDAQ: ARIA) from $9 to $11 and maintains its Buy rating.

JP Morgan has published a research report on Ariad Pharmaceuticals (NASDAQ: ARIA) after the company announced its Phase 3 SUCCEED trial hit its primary endpoint. In the report, JP Morgan writes "We reiterate our OW rating on ARIA following this morning's announcement that the Phase 3 SUCCEED trial...

Jefferies & Company has raised the price target on Ariad Pharmaceuticals (NASDAQ: ARIA) from $5 to $8 and maintains its Buy rating.

Key driver for ARIAD Pharmaceuticals (NASDAQ: ARIA) is ponatinib in pivotal Ph2, targeting well-defined/proven CML market (data 2H12), Jefferies reports. “As we assume no further milestones from MRK on ridaforolimus, if Ph3 succeeds (data in 1Q11), this would provide a significant upside to current...